Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthcare Services (HCSG) Cash & Equivalents (2016 - 2025)

Healthcare Services (HCSG) has disclosed Cash & Equivalents for 17 consecutive years, with $125.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 120.5% to $125.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $125.2 million, a 120.5% increase, with the full-year FY2025 number at $125.2 million, up 120.5% from a year prior.
  • Cash & Equivalents was $125.2 million for Q4 2025 at Healthcare Services, up from $124.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $125.2 million in Q4 2025 to a low of $16.2 million in Q1 2023.
  • A 5-year average of $58.8 million and a median of $43.6 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 75.33% in 2022, then skyrocketed 359.76% in 2025.
  • Healthcare Services' Cash & Equivalents stood at $70.8 million in 2021, then plummeted by 62.88% to $26.3 million in 2022, then soared by 106.74% to $54.3 million in 2023, then increased by 4.5% to $56.8 million in 2024, then soared by 120.5% to $125.2 million in 2025.
  • Per Business Quant, the three most recent readings for HCSG's Cash & Equivalents are $125.2 million (Q4 2025), $124.4 million (Q3 2025), and $82.8 million (Q2 2025).